FBI Launches Investigation into Former NFL Owner's Death and Drug Use
The Federal Bureau of Investigation has officially launched a comprehensive investigation into the circumstances surrounding the death of Jim Irsay, the former owner of the Indianapolis Colts. This probe is specifically focusing on his documented history of drug use and his professional relationship with a prominent addiction specialist.
Grand Jury Subpoena and Key Focus Areas
A federal grand jury has reportedly issued a subpoena requesting detailed information concerning several critical aspects of the case. The subpoena seeks documentation related to Irsay's untimely death last May at the age of 65, his extensive use of both illegal and prescription substances, and his connection to Dr. Harry Haroutunian, a noted addiction specialist.
This development follows initial statements from the Colts organization, which had previously announced that Irsay "passed away peacefully in his sleep." However, subsequent reports have painted a more complex picture of his final months.
Secret Relapse and Alleged Overdoses
According to emerging information, Jim Irsay, who had a long and public history of addiction struggles, secretly relapsed in the months leading up to his death. Reports indicate he was receiving ketamine injections and opioid pills directly from Dr. Haroutunian during this period.
Furthermore, it is alleged that Irsay suffered two separate drug overdoses in late 2023, which were not publicly disclosed at the time. These incidents are now a central focus of the federal investigation, as authorities seek to understand the full scope of his drug use and the medical care he received.
Parallels to Previous High-Profile Case
This federal investigation bears notable similarities to another recent high-profile case involving a celebrity death. The FBI and federal prosecutors previously brought charges in connection with the fatal drug overdose of actor Matthew Perry.
In that case, doctors who provided ketamine to Perry ultimately pleaded guilty to related charges. The current probe into Irsay's death suggests a broader federal effort to scrutinize medical professionals who may be improperly prescribing controlled substances to high-profile individuals with addiction histories.
The investigation remains ongoing, with federal authorities examining whether any laws were broken in the provision of drugs to Irsay during his final months. The outcome could have significant implications for how addiction treatment is monitored and regulated, particularly for individuals in the public eye.
